---
trial_id: 252
discovery_date: 2022-03-29 21:28:27.950753
date: 2022-03-29 21:28:27.950753
title: "Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to TysabriÂ® in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)"
summary: |
  <p>EudraCT Number: 2018-004751-20<br />Sponsor Protocol Number: PB006-03-01<br />Sponsor Name: Polpharma Biologics S.A.<br />Start Date: 2019-07-22<br />Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/PL">PL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/HR">HR</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004751-20'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2018-004751-20<br />Sponsor Protocol Number: PB006-03-01<br />Sponsor Name: Polpharma Biologics S.A.<br />Start Date: 2019-07-22<br />Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/PL">PL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/HR">HR</a> (Completed)</p>